A number of research firms have changed their ratings and price targets for NuVasive (NASDAQ: NUVA):

  • 8/2/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $80.00 price target on the stock.
  • 7/31/2017 – NuVasive was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Gabelli.
  • 7/31/2017 – NuVasive was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NuVasive’s second-quarter 2017 performance was mixed with the bottom line beating the estimates and sales missing the mark. However, year-over-year, revenue growth was solid, led by robust performance in the international market on above-market growth across all geographies. Notably, over the recent past, the company has demonstrated steady year-over-year improvement on the top-line front on account of strong procedural growth in the U.S. as well as internationally. We are optimistic about the company’s recent progress in development of technologies and services for spine surgery. On the flip side, over the last three months, NuVasive has been trading below the broader industry. Further, currency headwind, pricing and reimbursement issues along with a competitive landscape are major downsides. Also, the company’s low-margin Biotronic business impacted the second quarter’s performance.”
  • 7/30/2017 – NuVasive had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $83.00 price target on the stock, down previously from $90.00.
  • 7/30/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $79.00 price target on the stock.
  • 7/28/2017 – NuVasive had its “hold” rating reaffirmed by analysts at Needham & Company LLC. They wrote, “NUVA’s 2Q17 revenue missed and EPS beat consensus and management maintained its 2017 guidance. Pro forma revenue growth slowed to 5% in 2Q17 from 6% in 1Q17 as biologics sales continued to decline and operational challenges arose from the relocation of a neuromonitoring billing and collection department. NUVA’s operating margin beat consensus and increased 40 bps Y/Y. Despite NUVA’s slower revenue growth, management still expects revenue growth to accelerate in 2H17 given easier comps, new products, new customer wins, and new sales reps coming off non-competes.””
  • 7/28/2017 – NuVasive was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $72.00 price target on the stock, down previously from $79.00.
  • 7/28/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $80.00 price target on the stock.
  • 7/25/2017 – NuVasive had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $88.00 price target on the stock, up previously from $84.00.
  • 7/20/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $85.00 price target on the stock.
  • 7/19/2017 – NuVasive was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/5/2017 – NuVasive had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $90.00 price target on the stock.
  • 7/4/2017 – NuVasive was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “For the last three months, NuVasive has been trading above the Zacks categorized Medical Product industry. Over the recent past, the company has demonstrated steady year-over-year improvement on the top-line front on account of strong procedural growth in the U.S. as well as internationally. NuVasive’s strong momentum in the U.S. and international businesses in the last-reported first quarter also raises optimism. We are also optimistic about the company’s recent progress in development of technologies and services for spine surgery. On the flip side, the stock’s valuation is quite stretched. Further, currency headwind, pricing and reimbursement issues and competitive landscape are major downsides. Also, per management, the company’s low-margin Biotronic business impacted the last reported first quarter’s performance.”
  • 6/30/2017 – NuVasive had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $84.00 price target on the stock.
  • 6/28/2017 – NuVasive was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/28/2017 – NuVasive had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $90.00 price target on the stock, up previously from $85.00.
  • 6/27/2017 – NuVasive was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Over the last three months, NuVasive has been trading below the broader Medical Products industry. The stock’s valuation is also quite stretched. Further, currency headwind, pricing and reimbursement issues and competitive landscape are major downsides. Also, per management, the company’s low-margin Biotronic business impacted the last reported first quarter’s performance. However, the year-over-year improvement on the top-line front is on account of strong procedural growth in the U.S. as well as internationally. NuVasive’s strong momentum in the U.S. and international businesses in the first quarter raises optimism. We are also optimistic about the company’s recent progress in development of technologies and services for spine surgery.”
  • 6/12/2017 – NuVasive had its price target raised by analysts at Piper Jaffray Companies from $80.00 to $90.00. They now have an “overweight” rating on the stock.

Shares of NuVasive, Inc. (NUVA) traded down 1.98% during trading on Monday, hitting $64.49. The company had a trading volume of 1,012,604 shares. The firm has a market capitalization of $3.28 billion, a P/E ratio of 101.56 and a beta of 1.06. The stock’s 50-day moving average is $76.85 and its 200 day moving average is $74.43. NuVasive, Inc. has a 52-week low of $56.70 and a 52-week high of $81.68.

NuVasive (NASDAQ:NUVA) last announced its earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The business had revenue of $260.60 million during the quarter, compared to the consensus estimate of $261.95 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that NuVasive, Inc. will post $2.00 earnings per share for the current fiscal year.

In other news, EVP Peter Michael Leddy purchased 7,850 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was purchased at an average cost of $63.88 per share, with a total value of $501,458.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.70% of the stock is currently owned by corporate insiders.

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Receive News & Ratings for NuVasive Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc and related companies with MarketBeat.com's FREE daily email newsletter.